Press Releases

26.09.2018 | Nanion Technologies places two SyncroPatch 384PE Instruments for Ion Channel Screening at Charles River Laboratories

LIVINGSTON, N.J., MUNICH, Germany, September 26, 2018: Nanion announced today that Charles River Laboratories has purchased two SyncroPatch 384PE high-throughput patch clamp instruments. This purchase reflects an investment in screening technologies and assay development, while accommodating the rising demand in contract service for globally shared clients. The instruments will be delivered to Charles River (Cleveland site; former ChanTest) in November of this year and will be used for various ion channel screening & profiling services, including cardiac safety screening, efficacy, and SAR studies.

続きを読む

19.09.2018 | Nanion Technologies and Ncardia Sign Co-Marketing and Support Agreement to enhance Options for Cardiac Researchers

MUNICH, Germany and COLOGNE, Germany, September 19, 2018-- Nanion Technologies GmbH, a leading provider of instrumentation for ion channel drug discovery and screening, and the Ncardia Group, a leading developer, manufacturer, and service provider of human induced pluripotent stem cells (iPSCs) for safety and efficacy testing announced today that they have entered into a joint marketing and sales promotion agreement.

続きを読む

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok